

Advanced imaging to improve treatment planning and patient outcomes for patients with advanced prostate cancer

Frequently Asked Questions

Key dates:

Expression of Interest Letters from Individuals Deadline: June 27, 2019

Invitations extended to Individuals to attend Planning Meeting: July 12, 2019

Planning Meeting in Toronto: September 23, 2019

Team Registration Deadline: October 15, 2019

Full Application Deadline: November 12, 2019

Review Panel Meeting and Reverse Site Visit in Toronto: December 9, 2019

Funding start date: January 1, 2020

All deadlines are 5:00 p.m. Eastern.

Q 1. What do I provide in the Expression of Interest Letter?

A. Your Expression of Interest Letter must include the following:

Cover letter (2-page maximum) to include:

- Name
- Email address
- Institution/Department that you represent (one representative per Institution, or Department where appropriate)
- Your current position
- How your area of expertise and experience is relevant (i.e. why should you be selected to attend the proposal planning meeting)
- If you cannot attend, the person you would nominate to attend in your place
- Identify additional personnel or expertise who you feel need to be represented at the planning meeting/ on the applicant team for the proposal

Funding and publications (1-page maximum): Selected related funding and publications

Q 2. How will participants in the meeting be selected?

A. PCC Staff will review the applicants and prepare a list of attendees for the Planning Meeting, selecting representative investigators from institutions (or departments) from across the country. We would expect the meeting will bring together a group of no more than 20 people. The names of all who submitted an Expression of Interest will be shared with the meeting attendees; all qualified independent investigators are eligible to be named on the application.

Q 3. What if more than one person from my institution submits an Expression of Interest?

A. PCC staff will try to avoid multiple representatives from any one institution or department. Others from any institution may still be part of the applicant team as appropriate.

Q 4. Do I have to be invited to/attend the Planning Meeting to be included in the application?

A. No, you do not need to attend the Planning Meeting to be included on the applicant team. The names

of all who submitted an Expression of Interest will be shared with the meeting attendees; all qualified independent investigators are eligible to be named on the application.

Q 5. What will happen at the Planning Meeting?

A. This is an opportunity for the group to determine the focus of the proposal, the approach the application will take, the team, and the person who will be the lead on preparing the application. While PCC staff will facilitate the organization of the meeting; the participants attending will determine the direction of the meeting.

Q 6. What if the team decides to develop more than one proposal to meet the goal of the RFA?

A. While it is our intention that the group would submit one collaborative application, if it is apparent that multiple applications are best, PCC will accommodate more than one applicant team. However, this will create a competition for funding if the available pool of funding is not enough to support multiple applications.

Q 7. How will the application be created and submitted?

A. Following the Planning Meeting, a nominated Project Leader/Principal Investigator for the purposes of submitting the application must be identified. PCC staff will create the application template in the online system at pccgrants.smartsimple.ca and provide access to the Principal Investigator. Specific elements of the application are required to be completed by October 15, 2019, and the full application must be submitted online by the deadline of November 12, 2019. All deadlines are 5:00 p.m. Eastern time. All application elements are outlined in the RFA document.

Q 8. What if the Review Panel determines the application is not ready for approval?

A. The review panel can select 3 options as they review an application at the December Panel meeting: 1) to fund the program as is, 2) fund the program pending recommended changes, or 3) not to fund the proposal. Should the review panel determine the program approval is pending recommended changes, a revised application may be required to allow the applicant team to respond to the recommendations prior to approval.

This document will be updated as additional questions are identified.

Last updated: May 22, 2019